GlassScriptPhysician profile
Douglas Sessions
NPI 1932341005
$927.97
in general payments reported to CMS, 2019-2025
15 companies · $84.93 in 2025
The $84.93 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $192 · 2023: $338 · 2024: $50.38 · 2025: $84.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $237.94 | 2021-2024 | Surgiflo Hemostatic Matrix, Surgicel Nu-Knit, Vistaseal |
| Sanara Medtech INC. | $167.70 | 2021 | |
| Zimmer Biomet Holdings, INC. | $140.28 | 2023 | Comprehensive Shoulder System |
| Smith+Nephew, INC. | $89.62 | 2022-2023 | Coblation |
| Heron Therapeutics, INC. | $65.97 | 2022 | |
| Convatec INC. | $32.82 | 2023 | |
| Davol INC. | $31.58 | 2023-2025 | |
| Innovation Technologies INC | $27.59 | 2025 | Irrisept |
| Pacira Pharmaceuticals Incorporated | $24.15 | 2023 | Exparel, Zilretta, Iovera |
| Vertex Pharmaceuticals Incorporated | $21.45 | 2025 | |
| Vericel Corporation | $19.69 | 2021 | |
| Csl Behring | $18.78 | 2021 | |
| Dynasplint Systems INC. | $17.58 | 2025 | Dynasplint |
| Kowa Pharmaceuticals America, INC. | $16.60 | 2023 | Seglentis |
| Depuy Synthes Sales INC. | $16.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Sessions listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.